Please login to the form below

Not currently logged in
Email:
Password:

BIAL

This page shows the latest BIAL news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.

Latest news

  • Bial launches video campaign for World Parkinson’s Day Bial launches video campaign for World Parkinson’s Day

    Bial launches video campaign for World Parkinson’ s Day. Aims to challenge negative portrayals of people with the disease. ... Portugal-based pharma company Bial has launched a video campaign, ‘Me At My Best’, to raise awareness of Parkinson’s

  • Pharma's reputation on the wane, say patient groups Pharma's reputation on the wane, say patient groups

    Rounding out the bottom five were Stada, Bial (which was hit by a drug testing tragedy last year) and Novartis' Sandoz subsidiary.

  • EU proposes reforms to make first-in-human trials safer EU proposes reforms to make first-in-human trials safer

    EU proposes reforms to make first-in-human trials safer. New guideline revision paper “ takes into account lessons learnt” from fatal Bial trial. ... A subsequent inquiry by the French government put contract research organisation (CRO) Biotrial and

  • EC approves Bial’s Parkinson’s disease therapy EC approves Bial’s Parkinson’s disease therapy

    EC approves Bial’ s Parkinson’ s disease therapy. Ongentys will be given a phase roll-out in 2016 and 2017. ... Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors

  • Firms at fault in fatal clinical trial, says French government Firms at fault in fatal clinical trial, says French government

    The trial involved 90 healthy volunteers who were given Bial's BIA 10-2474 - a candidate drug for mood and motor disorders associated with neurodegenerative disorders and anxiety. ... It has been shown that it is … Bial's compound, by its unexpected

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Former Roche CEO joins BIAL board Former Roche CEO joins BIAL board

    Former Roche CEO joins BIAL board. Franz Humer to advise Portuguese pharma company. ... His incorporation is especially relevant to BIAL as it is a recognition of the work we have been developing.".

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics